Epizyme, Inc. (NASDAQ:EPZM)‘s stock had its “outperform” rating reiterated by Leerink Swann in a report issued on Thursday, The Fly reports. They presently have a $22.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $28.00. Leerink Swann’s target price suggests a potential upside of 31.74% from the stock’s previous close.

Several other brokerages have also issued reports on EPZM. Jefferies Group LLC assumed coverage on Epizyme in a report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price target on the stock. Cann reiterated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Tuesday, September 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Tuesday, September 19th. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, October 16th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $20.00 price target on shares of Epizyme in a report on Friday, September 15th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $22.67.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.02.

ILLEGAL ACTIVITY NOTICE: “Epizyme’s (EPZM) Outperform Rating Reaffirmed at Leerink Swann” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/epizymes-epzm-outperform-rating-reaffirmed-at-leerink-swann.html.

In related news, Director David M. Mott bought 200,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at $91,500. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $16.81, for a total value of $252,150.00. Following the completion of the transaction, the insider now owns 23,123 shares in the company, valued at approximately $388,697.63. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock worth $733,950 in the last 90 days. Corporate insiders own 25.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Fox Run Management L.L.C. bought a new position in shares of Epizyme in the third quarter valued at approximately $223,000. Lord Abbett & CO. LLC bought a new position in shares of Epizyme in the second quarter valued at approximately $9,726,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Epizyme by 3.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 1,068 shares in the last quarter. State Street Corp lifted its holdings in shares of Epizyme by 59.6% in the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after purchasing an additional 658,727 shares in the last quarter. Finally, Palo Alto Investors LLC lifted its holdings in shares of Epizyme by 18.9% in the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after purchasing an additional 907,245 shares in the last quarter. Institutional investors own 72.20% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

The Fly

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.